AIM ImmunoTech Inc. (AMEX: AIM) Reports Q1 Earnings, Advances Pancreatic Cancer Drug Ampligen

Font: Financial Modeling Prep  • May 16, 2026

• AIM ImmunoTech Inc. reported mixed Q1 2026 financial results, missing analyst EPS estimates but exceeding revenue expectations.
• The company is making significant progress in the clinical development of its drug candidate, Ampligen, particularly for pancreatic cancer, with positive data from a Named Patient Program and an ongoing Phase 2 clinical trial.
• To support its operations and ongoing research, AIM ImmunoTech Inc. secured approximately $4.2 million in gross proceeds through the exercise of warrants.

AIM ImmunoTech Inc. (AMEX: AIM) is an immuno-pharma company focused on researching and developing treatments for various cancers and immune-deficiency diseases. The company's main drug candidate is Ampligen (rintatolimod), which is being evaluated for its potential in treating diseases like pancreatic cancer. AIM operates in the competitive biotechnology sector.

On May 15, 2026, AIM reported its quarterly financial results. The company announced an earnings per share of -$0.69, which missed the analyst consensus estimate of -$0.37. However, AIM's revenue for the quarter came in at $22,000. This figure surpassed the analyst expectation of $20,781 for the same period.

The company's activities are heavily focused on the clinical development of Ampligen. As highlighted by GlobeNewswire, AIM recently hosted a virtual investor segment to discuss positive data for the drug in treating late-stage pancreatic cancer. This includes promising results from a Named Patient Program and an ongoing Phase 2 clinical trial.

To fund its operations, AIM announced an agreement to exercise certain warrants, generating approximately $4.2 million in gross proceeds. This move provides the company with working capital for general corporate purposes. Such financing is common for development-stage companies that are not yet profitable but have ongoing research expenses.

AIM's financial metrics reflect its development stage. The company has a negative trailing twelve-month Price-to-Earnings (P/E) ratio of -0.08, indicating it is not currently profitable. Its Price-to-Sales ratio is 9.16. The company maintains a low Debt-to-Equity ratio of 0.17, showing it has little debt compared to its equity.